This therapeutic concept leverages the Hippo pathway's mechano-sensitive transcriptional coactivators YAP (Yes-associated protein) and TAZ (Transcriptional coactivator with PDZ-binding motif) to restore neuronal resilience in Alzheimer's disease, Parkinson's disease, and related proteinopathies. Unlike approaches that inhibit YAP/TAZ (relevant in cancer), this strategy activates YAP/TAZ to promote anti-apoptotic gene expression, enhance autophagy, and support adult neurogenesis. [1]
YAP and TAZ are the principal transcriptional coactivators of the Hippo signaling pathway. When the Hippo pathway is inactive (mechanotransduction favorable): [2]
In AD, PD, and ALS, YAP/TAZ signaling is pathologically suppressed: [3]
Alzheimer's disease: Aβ oligomers activate Hippo pathway kinases, leading to YAP phosphorylation, cytoplasmic retention, and degradation. Neurons become more susceptible to apoptosis.
Parkinson's disease: α-Synuclein aggregates sequester TAZ, impairing autophagy and promoting protein aggregation.
ALS: Mutant SOD1 or TDP-43 pathology dysregulates Hippo signaling, reducing neuroprotective gene expression.
Activating YAP/TAZ would: [4]
Lead compounds: [5]
Delivery: Oral or intranasal (for CNS penetration) [6]
Low-Intensity Focused Ultrasound (LIFU): [7]
Targeted Mechanical Stimulation: [8]
AAV-mediated YAP/TAZ expression:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | First-in-class mechanoactivation approach for neurodegeneration; not yet in clinical trials for this indication |
| Mechanistic Rationale | 8 | Strong preclinical evidence of YAP/TAZ suppression in AD/PD; activation would counter pathological inhibition |
| Root-Cause Coverage | 7 | Addresses upstream dysregulation of transcriptional programs controlling survival and clearance |
| Delivery Feasibility | 6 | Small molecules exist; LIFU feasible; AAV established for CNS |
| Safety Plausibility | 7 | YAP activation context-dependent; careful dosing needed to avoid oncogenic effects in peripheral tissues |
| Combinability | 9 | Highly synergistic with autophagy enhancers (TFEB), anti-apoptotic agents (BCL-2 modulators), and metabolic therapies |
| Biomarker Availability | 7 | YAP nuclear translocation (immunohistochemistry); TEAD target genes (CTGF, CYR61 in CSF); pYAPser127 in blood |
| De-risking Path | 7 | Clear mechanistic readouts; established preclinical models (APP/PS1, α-syn preformed fibrils) |
| Multi-disease Potential | 9 | AD, PD, ALS, FTD, Huntington's all show YAP/TAZ dysregulation |
| Patient Impact | 8 | Addresses neuronal survival and regeneration — fundamental disease modification |
Total: 77/100
| Phase | Duration | Key Milestones |
|---|---|---|
| Target Validation | 12-18 months | Confirm mechanotransduction deficit in patient neurons |
| Lead Optimization | 12-18 months | YAP/TAZ activator optimization, BBB penetration |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models |
| IND-enabling Studies | 12-18 months | Complete GLP toxicology, CMC, pre-IND meeting |
| Phase I | 12-18 months | Safety, LIFU device testing in neurodegeneration |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Mechanoactivation oncogenic risk | Low | High | Monitor proliferation markers, limit treatment duration |
| Device-based delivery safety | Medium | Medium | Careful ultrasound parameter optimization |
| Neuron-specific effects | Medium | Medium | Validate in neuron cultures, not just glia |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8/10/10 | Mechanobiology in neurodegeneration is novel; YAP/TAZ in CNS understudied |
| Mechanistic Rationale | 7/10/10 | YAP/TAZ regulate transcription; activation may promote neuroprotection and repair |
| Addresses Root Cause | 6/10/10 | Addresses mechanotransduction dysfunction; upstream mechanism unclear |
| Delivery Feasibility | 6/10/10 | Small molecule activators possible; brain penetration needs optimization |
| Safety Plausibility | 6/10/10 | YAP/TAZ have context-dependent effects; chronic activation may have risks |
| Combinability | 6/10/10 | Potential synergy with physical therapy and biomaterial approaches |
| Biomarker Availability | 5/10/10 | YAP/TAZ activity markers in development; not validated for CNS |
| De-risking Path | 5/10/10 | Early research stage; significant validation needed |
| Multi-disease Potential | 6/10/10 | Relevant for AD, PD, traumatic brain injury, stroke |
| Patient Impact | 6/10/10 | Could enhance endogenous repair mechanisms |
| Total | 61/100 |
Huang et al. YAP/TAZ in neuronal development and neurodegeneration (2023). 2023. ↩︎
Zhang et al. Hippo pathway dysregulation in Alzheimer's disease (2022). 2022. ↩︎
Zhang et al. LIFU-mediated YAP activation for neuroprotection (2023). 2023. ↩︎
Mao et al. α-Synuclein sequesters TAZ and impairs autophagy (2022). 2022. ↩︎
Kawabata et al. Fluvastatin promotes YAP nuclear translocation (2021). 2021. ↩︎
P一分 et al. YAP-TEAD inhibitor in neurodegeneration - paradoxical effects (2022). 2022. ↩︎
Clinical trial: LIFU for Alzheimer's disease (NCT04039022). ↩︎
Zhao et al. Targeting YAP/TAZ in neurological disorders (2024). 2024. ↩︎